ROYAL BANK OF CANADA - NYMOX PHARMACEUTICAL CORP ownership

NYMOX PHARMACEUTICAL CORP's ticker is NYMX and the CUSIP is P73398102. A total of 46 filers reported holding NYMOX PHARMACEUTICAL CORP in Q3 2018. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
ROYAL BANK OF CANADA ownership history of NYMOX PHARMACEUTICAL CORP
ValueSharesWeighting
Q2 2023$01,430
+74.4%
0.00%
Q3 2022$0820
+391.0%
0.00%
Q2 2022$01670.0%0.00%
Q1 2022$01670.0%0.00%
Q4 2021$01670.0%0.00%
Q3 2021$0
-100.0%
167
-98.1%
0.00%
Q2 2021$14,000
+27.3%
8,829
+77.3%
0.00%
Q1 2021$11,000
+450.0%
4,979
+397.9%
0.00%
Q4 2020$2,000
-81.8%
1,000
-77.8%
0.00%
Q3 2020$11,000
-56.0%
4,500
-35.7%
0.00%
Q2 2020$25,000
+56.2%
7,0000.0%0.00%
Q1 2020$16,000
+6.7%
7,0000.0%0.00%
Q4 2019$15,000
-31.8%
7,000
-41.7%
0.00%
Q3 2019$22,000
+22.2%
12,000
-3.9%
0.00%
Q2 2019$18,000
+63.6%
12,490
+127.5%
0.00%
Q1 2019$11,000
+57.1%
5,4900.0%0.00%
Q4 2018$7,000
-50.0%
5,490
-4.5%
0.00%
Q3 2018$14,000
-46.2%
5,750
-26.7%
0.00%
Q2 2018$26,000
+73.3%
7,841
+122.4%
0.00%
Q1 2018$15,000
+275.0%
3,526
+172.3%
0.00%
Q4 2017$4,000
-90.5%
1,295
-88.0%
0.00%
Q3 2017$42,000
+13.5%
10,783
+27.2%
0.00%
Q2 2017$37,000
+27.6%
8,475
+5.9%
0.00%
Q1 2017$29,000
+31.8%
8,0000.0%0.00%
Q4 2016$22,000
-15.4%
8,0000.0%0.00%
Q3 2016$26,000
+30.0%
8,000
+33.3%
0.00%
Q2 2016$20,000
+42.9%
6,0000.0%0.00%
Q1 2016$14,000
-26.3%
6,0000.0%0.00%
Q4 2015$19,0006,0000.00%
Other shareholders
NYMOX PHARMACEUTICAL CORP shareholders Q3 2018
NameSharesValueWeighting ↓
First Citizens Financial Corp 35,100$125,0000.13%
Patriot Financial Group Insurance Agency, LLC 65,250$232,0000.09%
Willow Creek Wealth Management Inc. 24,224$86,0000.04%
WEBSTER BANK, N. A. 60,000$213,0000.03%
HighPoint Advisor Group LLC 34,000$123,0000.03%
Brown Advisory Securities, LLC 28,000$92,0000.02%
WMS Partners, LLC 18,000$64,0000.01%
Virtu Financial LLC 28,140$100,0000.01%
WEDBUSH SECURITIES INC 31,600$112,0000.01%
Squarepoint Ops LLC 62,214$221,0000.00%
View complete list of NYMOX PHARMACEUTICAL CORP shareholders